Rubicon Research IPO Allotment Out: Check Status, Latest GMP & Listing Date Here!
Rubicon Research IPO Allotment Out: The traders and investors' focus on Rubicon Research IPO allotment out, following an astonishing 103.9× subscription, is scrambling to check their status ahead of the October 16 listing.
Rubicon Research IPO Allotment Out: How to Check Allotment Status
The Rubicon Research IPO allotment out on October 14, 2025, and refunds/shares will be credited starting October 15. The official listing is set for Thursday, October 16 on both BSE and NSE.
Step-by-Step: Checking Your Allotment
You can verify your Rubicon Research IPO allotment via:
- Registrar (MUFG Intime) — Visit the IPO portal (in.mpms.mufg.com/Initial_Offer/public-issues.html), select Rubicon Research, enter PAN / Application No / DPID-Client ID, complete captcha, click “Submit.”
- BSE Website — Go to Investor → IPO Allotment Status, choose “Equity”, pick Rubicon Research, enter PAN / DP / App No.
- NSE Portal — Access the IPO section, select the company, then input your PAN or application number.
Once submitted, your allocation status (allotted or not) shows immediately. If not allotted, refunds begin October 15 (via bank/UPI mandates).
Subscription & GMP — What the Numbers Say
The IPO drew a jaw-dropping 103.9× subscription by the close of bidding (Oct 13). Bids ran into 1,70,96,80,620 shares for just 1,64,55,670 shares on offer.
Here’s a breakdown by investor category:
| Investor Category | Subscription (×) |
|---|---|
| QIB (Institutions) | 130.26× |
| NII (Non-Institutional) | 97.61× |
| RII (Retail Investors) | 35.47× |
Before listing, the Rubicon Research IPO Grey Market Premium (GMP) was trading from ₹95 to ₹128. Based on the upper price band (₹485), estimated GMP implied a listing target around ₹613–₹622 (premium ~26%–28%)
Financials & Business Strengths
Rubicon Research is a specialty pharmaceutical formulations firm, focused almost entirely on regulated markets, especially the U.S.
Growth Metrics & Margins
From FY 2023 to FY 2025, Rubicon clocked a CAGR of ~75.89 %, making it among India’s fastest-growing pharma players.
Key financials:
| Metric | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|
| Revenue (₹ crore) | ~418.9 | ~872.3 | ~1,284.3 |
| EBITDA Margin | ~10.49% | ~19.84% | ~20.67% |
| Net Profit (PAT) | –16.8 | ~91.0 | ~134.3 |
| PAT Margin | –4.03% | ~10.43% | ~10.37% |
| ROCE / Return on Equity (ROE) | ~1.35% / – | ~18.62% / ~27% | ~26.45% / ~29% |
Rubicon also invests heavily in R&D (~10.4% of revenue), compared to 2–8% for many pharmaceutical peers. The company holds 72 active ANDAs and 9 NDAs, and achieved a strong commercialisation rate of 86.4 % in the U.S. market.
One standout: among its 66 commercialised U.S. products, 9 products held more than 25% value market share in FY 2025.
Peer Comparison & Valuation
Analysts compare Rubicon’s performance metrics favorably against giants like Sun Pharma, Dr. Reddy’s, and Lupin. Its ROCE of ~26–27 % and EBITDA margins above 20% stand tall in the industry.
However, valuation is steep. At the upper band, it commands ~59× P/E and ~32× EV/EBITDA, raising concerns of a premium price entry.
Key Risks & What to Watch
While many growth signals shine, prudent investors must consider potential headwinds:
- Revenue concentration: Nearly 98% of revenue stems from the U.S. market.
- Client concentration: Top 5 clients contribute over 70% of revenue. Losing one major client could dent earnings.
- Regulatory risk: U.S. FDA audits, changing regulations or litigations pose a latent threat.
- Valuation stretch: The steep multiples already baked into the issue leave limited room for error.
- Working capital intensity: The business demands significant inventory and receivables, affecting cash flow.
Conclusion & Takeaway
The Rubicon Research IPO is among the most aggressively subscribed offerings of 2025. Its combination of growth, R&D orientation, and U.S. focus make it compelling. But high valuation and concentrated risks mandate caution.
For investors: As Rubicon Research IPO allotment out and if you receive allotment, enjoy potential listing upside. But if high multiples make your entry point steep, consider a measured start or partial position. Track quarterly U.S. revenue trends, FDA updates, and client-level disclosures closely in coming quarters.
Click Here to know more market & IPO related news and updates.
Disclaimer: The views and investment insights provided here are based on publicly available information and do not constitute financial advice. Readers are advised to conduct their own research or consult certified financial experts before making investment decisions.
